Advertisement
Advertisement
U.S. markets open in 3 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
56.70+0.42 (+0.75%)
As of 11:50AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close56.28
Open56.28
Bid56.71 x 28400
Ask56.73 x 2100
Day's Range56.28 - 56.92
52 Week Range46.70 - 67.99
Volume435,063
Avg. Volume2,540,774
Market Cap55.703B
Beta (5Y Monthly)1.12
PE Ratio (TTM)11.86
EPS (TTM)4.78
Earnings DateFeb 28, 2023
Forward Dividend & Yield2.00 (3.57%)
Ex-Dividend DateMay 02, 2022
1y Target Est74.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BAYN.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Bayer investor calls for swift replacement of CEO: newspaper

      Bayer investor Deka has called for CEO Werner Baumann to be replaced ahead of his scheduled departure, adding to mounting pressure on the German drugmaker. "Bayer needs a new strategic positioning, which cannot be credibly accomplished under Werner Baumann," Ingo Speich, head of sustainability and corporate governance at Deka, told the Frankfurter Allgemeine Sonntagszeitung (FAS) newspaper in remarks published on Saturday. The mutual funds firm is among Bayer's 20 largest shareholders.

    • Financial Times

      Bayer: activist could revive fortunes of chemical group

      Does Bayer’s C-suite have sufficient chemistry with its shareholders? The recent addition of two activist investors suggests maybe not. Jeff Ubben at Inclusive Capital Partners thinks the current management team is too tight-knit and wants Bayer to hire a new chief executive from outside.

    • Motley Fool

      The Top Healthcare Stocks to Buy With $100

      Bayer Aktiengesellschaft (OTC: BAYR.Y) and AstraZeneca (NASDAQ: AZN) are elite healthcare companies with shares that trade for less than $100 and make excellent long-term investments because of their revenue and earnings growth, promising pipelines, and above-average dividends. Bayer was down 11.2% in 2022 and currently trades for about $15 a share while AstraZeneca was up 16.4% in 2022 and currently trades for around $70 a share. Bayer is a huge German life science conglomerate.

    Advertisement
    Advertisement